77278-68-3

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-(2-thienylmethyl)-, 1,1-dimethylethyl ester
• Synonyms: 1,1-dimethylethyl 4-(2-thienylmethyl)-1-piperazinecarboxylate
• CAS NO: 77278-68-3
• Molecular Formula: C14H22N2O2S
• Molecular Weight: 282.40200
• Mol File: 77278-68-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-(2-thienylmethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-(2-thienylmethyl)-, 1,1-dimethylethyl ester(77278-68-3)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-(2-thienylmethyl)-, 1,1-dimethylethyl ester(77278-68-3)

Safety Data

• Hazardous Substances Data: 77278-68-3(Hazardous Substances Data)

Usage

Molecular weight

290.36 g/mol

Structure

A piperazine ring with a carboxylic acid group and a 2-thienylmethyl ester group attached to the 1 and 4 positions, respectively.

Appearance

White or off-white crystalline solid

Solubility

Slightly soluble in water, soluble in organic solvents such as ethanol and methanol.

Use

Commonly used as an intermediate in organic synthesis and pharmaceutical manufacturing, with potential applications in drug development.

Biological activity

Known for its diverse range of biological activities, making it a valuable component in the pharmaceutical and medical industries.

Safety

It is important to handle this chemical with care and follow proper safety protocols to avoid harm.

Upstream product

• 98-03-3 thiophene-2-carbaldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 765-50-4 2-Chloromethylthiophene 

Downstream Products

• 39244-79-6 1-(thien-2-ylmethyl)piperazine 
• 163839-10-9 1-(2-thienylmethyl)piperazine, monohydrochloride 

Relevant articles and documents

Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer

Poly (ADP-ribose) polymerase-1 (PARP-1) is a potential target for the discovery of chemosensitizers and anticancer drugs. Amentoflavone (AMF) is reported to be a selective PARP-1 inhibitor. Here, structural modifications and trimming of AMF have led to a series of AMF derivatives (9a-h) and apigenin-piperazine/piperidine hybrids (14a-p, 15a-p, 17a-h, and 19a-f), respectively. Among these compounds, 15l exhibited a potent PARP-1 inhibitory effect (IC50 = 14.7 nM) and possessed high selectivity to PARP-1 over PARP-2 (61.2-fold). Molecular dynamics simulation and the cellular thermal shift assay revealed that 15l directly bound to the PARP-1 structure. In in vitro and in vivo studies, 15l showed a potent chemotherapy sensitizing effect against A549 cells and a selective cytotoxic effect toward SK-OV-3 cells through PARP-1 inhibition. 15l·2HCl also displayed good ADME characteristics, pharmacokinetic parameters, and a desirable safety margin. These findings demonstrated that 15l·2HCl may serve as a lead compound for chemosensitizers and the (BRCA-1)-deficient cancer therapy.

INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures (Ia), (Ib) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use

The present invention provides substituted dibenzoxazepine and dibenzthiazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, and for prostaglandin-E2 mediated diseases, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal, and a method for treating prostaglandin-E2 mediated diseases in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.